Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
about
Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysisAminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes versus other antiviral drugs for chronic hepatitis CSofosbuvir: a novel oral agent for chronic hepatitis CRetrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women?Diabetes mellitus and metformin in hepatocellular carcinomaSystematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Sofosbuvir treatment and hepatitis C virus infectionManagement of immunosuppressant agents following liver transplantation: Less is moreEfficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-AnalysisChronic hepatitis C: This and the new era of treatmentRole of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus InfectionResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsHepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral TherapyHepatitis C: Treatment of difficult to treat patientsPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewFinally sofosbuvir: an oral anti-HCV drug with wide performance capabilitySurgical approach for hepatitis C virus-related hepatocellular carcinomaOncogenes and RNA splicing of human tumor virusesVertical transmission of hepatitis C virus: systematic review and meta-analysisAntiviral therapies for chronic hepatitis C virus infection with cirrhosisTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisEfficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-AnalysisConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionHepatitis C virus: Virology, diagnosis and treatmentHepatitis C.A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected PatientsGlobal epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypesPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsDaclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C.Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectivesHepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection TreatmentNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Sofosbuvir.Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.A consensus for occupational health management of healthcare workers infected with human immunodeficiency virus, hepatitis B virus, and / or hepatitis C virus.
P2860
Q24186846-450A9E1E-427F-4ABF-ABFA-4C43116B524EQ24193940-2EE6428C-D33C-4F06-B0C6-51E8FB741FB3Q24194815-CBC06118-4E47-4422-A87D-9ED8F8A3B75DQ24562950-3E8118A9-DDB4-40A2-89F1-43592304DD24Q24658656-75FFB382-5B6F-4925-9B51-F1D1C4C54F55Q26741205-B2067623-DB9B-48F7-9887-7475924198B9Q26768128-AC98120E-5D97-4C4C-B412-89F723F239EDQ26770024-949E5768-CA14-499C-B289-9BC65E7453D5Q26770033-723A0B66-5AF1-4A43-8A8B-3F5A760F41D3Q26771458-F53949E7-6DE6-44A7-8EEB-B2A90AF3990CQ26775011-05527894-91EB-4673-9236-66CE4A0682F0Q26776408-394E69DF-E800-40AF-A0B0-F26421FB216DQ26777408-8DD0D08F-4F33-43A6-A291-52E2E8E4138CQ26781743-86C1C0D2-122E-4069-A000-EEBBE25CBC58Q26798465-422BFDB7-5E19-4B34-85B2-3FAA9A11B505Q26798477-12F65D3F-8EA8-4B90-A146-88C486C95A4FQ26800050-E8944CA0-2DD5-45A8-995B-4E211B11F75BQ26822400-EBFBAE3C-1628-42C3-AF4E-86952983590DQ26824046-773108A4-5811-42F8-B3E6-7BEA9B0CCFAEQ26830643-D92E0D5B-5565-4D8D-9892-4AE1C084A9ABQ26865870-F64CEAD3-5A74-4F0F-8436-E28195E065EBQ27022794-04EA20BE-709C-4A7F-A2ED-B22C279EA1D4Q28070260-5BC634EC-BBDE-4905-BE43-4571B2D8BF40Q28074783-7714A968-BBEE-4891-9D6E-F4C70B352F75Q28075544-DECDEAD5-DB9D-4A77-BFCB-92BBCECFE430Q28082000-D161CD8E-74E7-496C-BB4F-00D2CBFC42C4Q28084654-6F0D0845-B051-433D-A9FE-22829401CB7BQ28546535-0E776383-67B7-4454-8EA3-0BB059FCC139Q30245058-3350706A-1E24-4EC4-B07D-F4D375A9D750Q30365599-38239019-A3E2-44A6-9EB7-1CD80635B5BBQ31170657-1F067931-36CE-4F21-8ADB-8ABFA9EDDA22Q33168181-AE29C9E6-ABB3-4C98-986D-E3D37AE02952Q33423299-A900ABF3-D6A3-40FD-BDB6-BC10DDAE03DFQ33440436-1C2090DC-546A-4AA2-A26F-239556EB7379Q33568568-BA1C7EBB-271E-406F-B43E-D2E76010083DQ33576161-80EE0D19-ECEB-421C-9112-44647E519910Q33672648-E68BDFF3-C87C-4188-B0A7-6AE794A9D153Q33774724-05824636-C1CB-4600-8DC9-3D7049E3926DQ33805907-B4036F84-E5FD-40B9-AF14-5B8C84D1B828Q33818464-B6AA705C-E69F-42F7-A85F-9104489B4B77
P2860
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@ast
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@en
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@nl
type
label
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@ast
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@en
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@nl
prefLabel
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@ast
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@en
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@nl
P2093
P921
P1433
P1476
Sofosbuvir and ledipasvir fixe ...... el, randomised, phase 2 trial.
@en
P2093
Eric Lawitz
Fernando E Membreno
Fred F Poordad
Hongmei Mo
John G McHutchison
Phillip S Pang
Robert H Hyland
William T Symonds
P304
P356
10.1016/S0140-6736(13)62121-2
P407
P577
2013-11-05T00:00:00Z